Received Apr 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| YF | YELLOW FEVER (YF-VAX) | SANOFI PASTEUR | UNK | UK324AB | — |
VARIVAX diluent was used to reconstitute the YF-VAX vaccine and was given to a patient with no AE; Initial information received on 07-Apr-2026 regarding an unsolicited valid non-serious case received from a healthcare professional (HCP). This case involves an unknown age patient of unknown gender who was administered to yellow fever vaccine (YF-VAX) with varivax diluent which was used to reconstitute the YF-VAX vaccine with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s), family history, concomitant medications were not provided. On an unknown date, the patient received a 1X dose of yellow fever vaccine (YF-VAX), solution for injection (batch: UK324AB, expiry date: 30-Nov-2026) (strength: unknown) via unknown route for immunization (Immunisation). A nurse manager called to report that varivax diluent was used to reconstitute the YF-VAX vaccine and was given to a patient (Product preparation error, Onset: unknown, Latency: unknown). She called to check if the dose should be repeated. Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE